CTLA4 and melanoma: With immune checkpoint inhibitors becoming increasingly common in the clinic it is unsurprising that anti‐RANKL therapies have been proposed for melanoma, both alone and in combination with anti‐CTLA‐4 therapies (Ahern et al., 2017; Smyth, Yagita, & McArthur, 2016).